Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
Not Applicable
- Conditions
- Thyroid CarcinomaMetastatic Sites Lung Bone Nodal
- Registration Number
- NCT00749697
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Brief Summary
The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.
- Detailed Description
Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. Patients will receive the standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for the protocol purpose.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- age above 18
- histological confirmation of the differentiated thyroid carcinoma available
- WHO performance score 0-2
- metastatic sites lung and/or bone and/or nodal (radiologically measurable disease > 1 cm)
- life expectancy > 6 months
- patient has undergone total/near total thyroidectomy
- no past history of sensitivity/reaction to 1311
Exclusion Criteria
- non iodine concentrating tumours
- received chemotherapy or radiotherapy in 6 weeks
- pregnant or breast feeding patients
- iodine contrast injection in last 3 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method The primary outcome measure is to correlate the predicted dose from the tracer study with the actual absorbed dose measure on the therapeutic scan
- Secondary Outcome Measures
Name Time Method The secondary outcomes will be to assess the response at 6 months post therapy in each patient
Trial Locations
- Locations (1)
Royal Marsden NHS Foundation Trust
🇬🇧London, Sutton, United Kingdom